Phase I Study of Veliparib (ABT-888) in Combination With Cisplatin Plus Gemcitabine in Advanced Biliary, Pancreatic, Urothelial, and Non-small Cell Lung Cancer.

Trial Profile

Phase I Study of Veliparib (ABT-888) in Combination With Cisplatin Plus Gemcitabine in Advanced Biliary, Pancreatic, Urothelial, and Non-small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2013

At a glance

  • Drugs Veliparib (Primary) ; Cisplatin; Gemcitabine
  • Indications Biliary cancer; Non-small cell lung cancer; Pancreatic cancer; Urogenital cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 11 Jul 2012 Planned end date changed from 1 Sep 2011 to 1 Jul 2014 as reported by ClinicalTrials.gov.
    • 03 Feb 2011 New trial record
    • 01 Feb 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top